Showing 1 to 1 of 1 results
dailymail.co.uk
🌐 85% Global Worthiness
NHS Approves Capivasertib for Advanced Breast Cancer
The NHS approved capivasertib, a twice-daily pill, for HR-positive HER2-negative breast cancer with specific gene mutations, benefiting up to 3,000 women yearly by extending progression-free survival by 4.2 months; this follows extensive research and clinical trials.
NHS Approves Capivasertib for Advanced Breast Cancer
The NHS approved capivasertib, a twice-daily pill, for HR-positive HER2-negative breast cancer with specific gene mutations, benefiting up to 3,000 women yearly by extending progression-free survival by 4.2 months; this follows extensive research and clinical trials.
Progress
36% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results